(Q42260849)

19 October 2017

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor (English)

1 reference

19 October 2017

1 reference

W Spreen

1

1 reference

19 October 2017

S Min

2

1 reference

19 October 2017

S L Ford

3

1 reference

19 October 2017

S Chen

4

1 reference

19 October 2017

Y Lou

5

1 reference

19 October 2017

M Bomar

6

1 reference

19 October 2017

M St Clair

7

1 reference

19 October 2017

S Piscitelli

8

1 reference

19 October 2017

T Fujiwara

9

1 reference

19 October 2017

1 September 2013

1 reference

19 October 2017

1 reference

19 October 2017

14

1 reference

19 October 2017

5

1 reference

19 October 2017

192-203

1 reference

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

19 October 2017

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Efavirenz in the therapy of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-192

21 January 2018

Identifiers

DOI

10.1310/HCT1405-192

1 reference

19 October 2017

1 reference